Photo via Fox News

New drug combo shrinks tumors in most patients facing aggressive cancer type

Read the original at Fox News ↗
Cite

Quill, K. (2026, November 21). New drug combo shrinks tumors in most patients facing aggressive cancer type. Fox News. https://www.foxnews.com/health/new-drug-combo-shrinks-tumors-most-patients-aggressive-cancer-type

Dated from the outlet's own feed. Check the original for its byline.

Fox News · collected 2026-11-21 · by Khloe Quill

Quick Summary

A new drug combination involving an experimental pill called daraxonrasib and standard chemotherapy has shown promising results in treating advanced pancreatic cancer. In a phase 1/2 trial presented at the EORTC-NCI-AACR Symposium in Barcelona, this combination shrank tumors or halted their growth in 90.2% of 61 patients, with 60.7% experiencing tumor shrinkage, including 8.2% who saw complete response. The median progression-free survival exceeded one year, nearly double that of standard chemotherapy alone. The study suggests the potential of targeting the RAS gene to improve outcomes for pancreatic cancer patients.
Written by AI on 2026-11-21, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

Scientists have reported a significant breakthrough in pancreatic cancer treatment with a new daily pill called daraxonrasib, which has shown promising results in early trials. In these trials, the cancer became undetectable in one in 12 patients who received the drug along with chemotherapy, and tumours stopped growing in nearly all of the 61 participants diagnosed with advanced pancreatic cancer that had spread to other parts of the body. Although the pill cannot yet be considered a cure, it offers hope for extending the lives of patients with one of the deadliest and hardest-to-treat cancers, which has the lowest survival rate of all common cancers in the UK. Dr. Sam Godfrey of Cancer Research UK described the development as "the biggest leap forward in decades."

Written for “Pill Breakthrough for Pancreatic Cancer” on 2026-11-21, grounded in this article and the 2 other(s) covering the same event.
Why this leaning score
This article does not take a side on a contested political question, so it has no leaning score. That is an answer rather than a gap: a match report or a rescue can be warmly or critically written without being left or right, and scoring it anyway is how approval of a subject gets recorded as a political position.
No political leaning scored for article 169076 · logged 2026-11-21

How they differ

3 outlets covered “Pill Breakthrough for Pancreatic Cancer”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

Fox NewsThis outlet21 Nov

A new drug combination involving an experimental pill called daraxonrasib and standard chemotherapy has shown promising results in treating advanced pancreatic cancer. In a phase 1/2 trial presented at the EORTC-NCI-AACR Symposium in Barcelona, this combination shrank tumors or halted their growth in 90.2% of 61 patients, with 60.7% experiencing tumor shrinkage, including 8.2% who saw complete response. The median…

New drug combo shrinks tumors in most patients facing aggressive cancer type (this article)
BBC20 Nov

Experts are heralding a daily pill called daraxonrasib as a major breakthrough in pancreatic cancer treatment, with some patients showing undetectable tumors on scans. In a trial involving 61 recently diagnosed patients with advanced pancreatic cancer, tumors stopped growing in 90% of participants, and for around 8%, or one in 12, tumors became undetectable. While this is considered highly promising, doctors…

Massive hope for pancreatic cancer pill after trial saw tumours vanish →
The Guardian20 Nov

Doctors are celebrating early results from a trial of a new pill called daraxonrasib for pancreatic cancer, which showed that in one in 12 patients, the cancer became undetectable. In the trial involving 61 patients with advanced cancer that had spread, tumours stopped growing in 90% of cases, and over 60% saw their tumours shrink or disappear. Dr. Wungki Park, who presented the findings at a symposium in Barcelona…

Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’ →

Compared with similar articles

This article reads unscored and hedges 9% of its claims. Each row says how that neighbour differs.
BBC News
Hedges 6 of 21 claims Outlet record 65/100

Story

Pill Breakthrough for Pancreatic Cancer
Health · 3 article(s) covering the same event. See how they differ ↑
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
22
sentences that state something as happening or true
Uncertain
9%
2 of 22 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
66/100
Fox News's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
3
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-21 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

Fox News · 8354 article(s) · 16 correction(s) detected
Running correction rate · 16 correction(s)

Who wrote this

Khloe Quill
30 article(s) here · 1 carrying a prediction
Separate studies would be needed to test whether the combination works in those diseases.
Replacing regular table salt with a potassium-enriched alternative could prevent nearly three million deaths and more than 10 million cases of heart and kidney disease worldwide every year, according to a major study published in Nature Health.
Most people infected with dengue experience mild or no symptoms, typically recovering within two weeks, according to Mayo Clinic.
People who lose weight through crash dieting or appetite-suppressing medications may shed muscle along with fat, experts warn.
" Some people may maintain friendships while leaving open the possibility of a future romantic relationship, Trombetti said.
"From a clinical perspective, is helpful to review medications with the autistic patient's physicians and, if possible, try to avoid medications that may cause a Parkinson's appearance."
While immediate effects may appear as hoarseness, coughing, or reduced athletic endurance, the larger impact poses risks to long-term vital organ function.
Brain games, crosswords and math puzzles are often promoted as ways to sharpen memory, but neurologists warn that generic exercises may not address the specific cause of mental fog.
While immediate effects may appear as hoarseness, coughing, or reduced athletic endurance, the larger impact poses risks to long-term vital organ function.
"Daytime napping may compensate for poor nighttime sleep, but it may also reduce the drive to sleep at night, potentially contributing to nighttime sleep disturbances, another important potential risk factor for dementia."
Also by Khloe Quill
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 30 articles by Khloe Quill →

Topics

Barcelona Memorial Sloan Kettering Cancer Center National Cancer Institute nab-paclitaxel the EORTC-NCI-AACR Symposium

Subjects

Barcelona ORG · 1× California GPE · 1× Elena Garralda PERSON · 1× Memorial Sloan Kettering Cancer Center ORG · 1× National Cancer Institute ORG · 1× New York GPE · 1× Revolution Medicines ORG · 1× Spain GPE · 1× Wungki Park PERSON · 1× the Vall d’Hebron Institute of Oncology ORG · 1×

Narrative

Dr. Elena Garralda, chair of the symposium and co-director of the clinical research program at the Vall d’Hebron Institute of Oncology in Spain, who was not involved in the research, said the results show that RAS-targeted drugs can be combined with existing treatments at the start of treatment to potentially achieve longer-lasting benefits.
framing: assertive · carried by 1 article(s) · first seen 2026-11-21
Separate studies would be needed to test whether the combination works in those diseases.

Claims (22 extracted, 2 hedged)

Pairing an experimental pill with standard chemotherapy shrank tumors or halted growth in most patients with advanced pancreatic cancer, according to early clinical trial results presented Friday at a major international cancer conference. uncertain
Pairing → pair → conference
The findings, shared at the EORTC-NCI-AACR Symposium in Barcelona, come from a phase 1/2 trial testing a daily oral medication called daraxonrasib, along with two standard intravenous chemotherapy drugs, gemcitabine and nab-paclitaxel. asserted
findings → share → drugs
The trial focused on 61 patients whose pancreatic cancer had already spread to other organs and who had not yet received treatment for their advanced disease. asserted
who → focus → disease
Pancreatic cancer is notoriously difficult to treat, because more than half of patients are diagnosed after the disease has already spread, research shows. asserted
research → treat → patients
In major clinical trials for metastatic pancreatic cancer, chemotherapy alone shrinks tumors in about 23% to 42% of patients, but the disease typically begins growing again after five to six months, and most patients survive between eight and 11 months. asserted
patients → shrink → months
According to National Cancer Institute data, only about 3% of patients with distant-stage disease live five years past diagnosis. uncertain
% → accord → diagnosis
In the new study, which tracked patients for a median follow-up of 18 months, tumors shrank in 60.7% of cases, including 8.2% where they disappeared entirely on scans. asserted
they → track → scans
Overall, the combination stopped tumor growth in 90.2% of participants. asserted
combination → stop → participants
Patients went a median of 12.8 months before their cancer worsened, almost double the timeframe typically seen with standard chemotherapy, and 76.6% were still alive at the one-year mark, the study found. " asserted
study → go → mark
We are now seeing not only substantial tumor shrinkages, including complete responses, but also durable disease control, with median progression-free survival exceeding one year," said study lead Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, in a press release. asserted
Park → see → release
More than 90% of pancreatic cancers are driven by a faulty gene called RAS, which allows tumors to keep growing. asserted
tumors → drive → gene
Daraxonrasib is designed to turn off that growth signal, something scientists long thought was impossible to fix with medication. asserted
scientists → design → medication
Dr. Elena Garralda, chair of the symposium and co-director of the clinical research program at the Vall d’Hebron Institute of Oncology in Spain, who was not involved in the research, said the results show that RAS-targeted drugs can be combined with existing treatments at the start of treatment to potentially achieve longer-lasting benefits. asserted
drugs → involve → benefits
Side effects included rash, diarrhea, fatigue and low blood cell counts linked to chemotherapy, most of which were manageable with standard care. asserted
most → include → care
Only 5% of patients stopped treatment because of side effects tied to daraxonrasib. asserted
% → stop → daraxonrasib
Researchers emphasized that the findings carry some limitations. asserted
findings → emphasize → limitations
Because this was an early-phase, single-group study involving 61 people, all participants received the experimental combination. asserted
participants → involve → combination
Without a direct comparison group of patients receiving standard chemotherapy alone, doctors cannot yet confirm how much better the new regimen performs or whether it definitively extends overall survival. asserted
it → receive → survival
The findings also apply strictly to metastatic pancreatic cancer, even though RAS mutations drive several other cancers, including certain lung, colorectal and gynecological cancers. asserted
mutations → apply → cancers
Separate studies would be needed to test whether the combination works in those diseases. asserted
combination → need → diseases
The trial was funded by Revolution Medicines, the California-based developer of daraxonrasib. asserted
trial → fund → daraxonrasib
To determine whether these early findings translate into a durable survival benefit, researchers have launched a larger, randomized phase 3 trial, called RASolute-303, which directly compares daraxonrasib — both on its own and combined with chemotherapy — against standard chemotherapy alone. asserted
which → determine → chemotherapy
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support